2016 Fiscal Year Final Research Report
Mechanism of amelioration of steatohepatitis with niacin (vitamin B3): the pursuit of novel target genes for the treatment of NASH
Project/Area Number |
26460174
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Environmental and hygienic pharmacy
|
Research Institution | Teikyo University |
Principal Investigator |
Hara Massumi 帝京大学, 医学部, 教授 (70420213)
|
Research Collaborator |
TSUNEYAMA Koichi 徳島大学, 医学部, 教授
TSUKAMOTO Kazuhisa 帝京大学, 医学部, 教授
KURANO Makoto 東京大学, 医学部, 講師
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | Niacin / NASH / PNPLA3 / apoA-IV |
Outline of Final Research Achievements |
ICR mouse neonatally administered monosodium glutamate (MSG) shows obesity, insulin resistance, and is a murine model of steatohepatitis. In this study, we analysed the effect of nicotinic acid on steatohepatitis of MSG-treated obese mice. After 12 weeks of treatment of niacin, MSG-treated mice showed less weight of body and liver. Histopathological analyses showed markedly prevention of steatohepatitis. NAFLD activity scores (NAS) of niacin and vehicle groups were 0.0, 5.2, respectively. Niacin also dramatically ameliorated accomplished steatohepatitis. Niacin treatment ameliorated dyslipidemia; atherogenic LDL fraction was disappeared in fasting plasma, and elevations of postprandial NEFA and triglycerides were suppressed. Mircoarray analyses showed that the genes of apolipoprotein A-IV and patatin-like phospholipase domain containing 3 (PNPLA3) were changed in expression with the treatment of niacin.
|
Free Research Field |
Metabolism
|